The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | The present and future of hemophilia A treatment
Eman Hassan, MD, Birmingham Children’s Hospital, Birmingham, UK, outlines current and emerging treatments for hemophilia A. Dr Hassan first talks on emicizumab, which has been very effective in reducing the frequency of bleeding episodes in patients with hemophilia A, and is able to change a severe hemophilia A phenotype into a mild phenotype. Dr Hassan also highlights ongoing clinical trials in patients with mild and moderate hemophilia A, as well as trials for gene therapy, which is expected to become a new standard of care in hemophilia A. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
